The latest price target for Boundless Bio (NASDAQ:BOLD) was reported by Guggenheim on December 13, 2024. The analyst firm set a price target for $0.00 expecting BOLD to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Boundless Bio (NASDAQ:BOLD) was provided by Guggenheim, and Boundless Bio downgraded their neutral rating.

There is no last upgrade for Boundless Bio

The last downgrade for Boundless Bio Inc happened on December 13, 2024 when Guggenheim changed their price target from N/A to N/A for Boundless Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Boundless Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Boundless Bio was filed on December 13, 2024 so you should expect the next rating to be made available sometime around December 13, 2025.

While ratings are subjective and will change, the latest Boundless Bio (BOLD) rating was a downgraded with a price target of $0.00 to $0.00. The current price Boundless Bio (BOLD) is trading at is $2.60, which is out of the analyst’s predicted range.